Prescriber Criteria Form

Xospata 2025 PA Fax 2808-A v1 010125.docx Xospata (gilteritinib) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673.** Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Xospata (gilteritinib).

Patier	nt Name:				
Patier	nt ID:				
Patier	nt DOB:	Patient Phone:			
Presc	riber Name:				
Presc	riber Address:				
City: Prescriber Phone: Diagnosis:		State:	Zip:		
		Prescriber Fax: ICD Code(s):			
_					
Pleas	se circle the appropriate answer for	each question.			
1	Does the patient have relapsed or r		ıkemia (AML)?	Yes	No
			kemia (AML)?	Yes	No
	Does the patient have relapsed or r	efractory acute myeloid leu	, ,	Yes Yes	No No
1	Does the patient have relapsed or r [If no, then skip to question 3.] Does the patient have an FMS-like (If unknown, please select 'No'.)	efractory acute myeloid leu	, ,		
1	Does the patient have relapsed or r [If no, then skip to question 3.] Does the patient have an FMS-like	efractory acute myeloid leu	, ,		
1	Does the patient have relapsed or r [If no, then skip to question 3.] Does the patient have an FMS-like (If unknown, please select 'No'.)	efractory acute myeloid leu	utation?		
2	Does the patient have relapsed or r [If no, then skip to question 3.] Does the patient have an FMS-like (If unknown, please select 'No'.) [No further questions.]	efractory acute myeloid leu	utation?	Yes	No
2	Does the patient have relapsed or r [If no, then skip to question 3.] Does the patient have an FMS-like (If unknown, please select 'No'.) [No further questions.] Does the patient have a myeloid, ly	efractory acute myeloid leutyrosine kinase 3 (FLT3) m	eoplasm?	Yes	No
2	Does the patient have relapsed or realist [If no, then skip to question 3.] Does the patient have an FMS-like (If unknown, please select 'No'.) [No further questions.] Does the patient have a myeloid, lye [If no, then no further questions.] Does the neoplasm have eosinophic rearrangement?	efractory acute myeloid leutyrosine kinase 3 (FLT3) m	eoplasm?	Yes	No
2	Does the patient have relapsed or r [If no, then skip to question 3.] Does the patient have an FMS-like (If unknown, please select 'No'.) [No further questions.] Does the patient have a myeloid, ly [If no, then no further questions.] Does the neoplasm have eosinophi	efractory acute myeloid leutyrosine kinase 3 (FLT3) m	eoplasm?	Yes	No

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

Prescriber (or Authorized) Signature: Date:	
---	--